Endologix (ELGX) Earns News Sentiment Score of 0.18

Share on StockTwits

News headlines about Endologix (NASDAQ:ELGX) have been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Endologix earned a news impact score of 0.18 on Accern’s scale. Accern also gave media coverage about the medical instruments supplier an impact score of 46.8587928489129 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the news headlines that may have impacted Accern’s analysis:

NASDAQ:ELGX traded down $0.09 on Tuesday, hitting $5.42. 4,339 shares of the stock were exchanged, compared to its average volume of 483,122. The firm has a market capitalization of $462.06 million, a PE ratio of -11.31 and a beta of 0.44. The company has a debt-to-equity ratio of 3.58, a current ratio of 2.13 and a quick ratio of 1.37. Endologix has a fifty-two week low of $3.75 and a fifty-two week high of $6.72.

Endologix (NASDAQ:ELGX) last announced its quarterly earnings results on Wednesday, May 2nd. The medical instruments supplier reported ($0.15) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.03. The company had revenue of $42.28 million during the quarter, compared to analyst estimates of $41.14 million. Endologix had a negative return on equity of 47.01% and a negative net margin of 35.86%. The firm’s revenue was down .8% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.18) earnings per share. research analysts anticipate that Endologix will post -0.7 earnings per share for the current year.

ELGX has been the subject of several analyst reports. BidaskClub upgraded Endologix from a “buy” rating to a “strong-buy” rating in a research note on Thursday, May 24th. ValuEngine lowered Endologix from a “sell” rating to a “strong sell” rating in a research note on Thursday, May 17th. Zacks Investment Research upgraded Endologix from a “sell” rating to a “hold” rating in a research note on Monday, May 7th. Stifel Nicolaus upped their target price on Endologix from $4.50 to $5.00 and gave the company a “hold” rating in a research note on Monday, May 21st. Finally, Oppenheimer set a $5.00 target price on Endologix and gave the company a “hold” rating in a research note on Thursday, May 3rd. One analyst has rated the stock with a sell rating, six have issued a hold rating, one has assigned a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $4.95.

About Endologix

Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system.

See Also: Understanding Analyst Recommendations

Insider Buying and Selling by Quarter for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

River & Mercantile Asset Management LLP Takes Position in Dropbox Inc
River & Mercantile Asset Management LLP Takes Position in Dropbox Inc
Prio Wealth Limited Partnership Lowers Stake in Dell Technologies Inc
Prio Wealth Limited Partnership Lowers Stake in Dell Technologies Inc
River & Mercantile Asset Management LLP Increases Stake in Stericycle Inc
River & Mercantile Asset Management LLP Increases Stake in Stericycle Inc
Weekly Investment Analysts’ Ratings Updates for Central Garden & Pet
Weekly Investment Analysts’ Ratings Updates for Central Garden & Pet
Sandy Spring Bank Decreases Holdings in Union Pacific Co.
Sandy Spring Bank Decreases Holdings in Union Pacific Co.
On Deck Capital  vs. Blackhawk Network  Head-To-Head Comparison
On Deck Capital vs. Blackhawk Network Head-To-Head Comparison


© 2006-2018 Ticker Report. Google+.